Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin

doi:10.1016/0006-2952(93)90079-C

Biochemical Pharmacology

Volume 45, Issue 2, 26 January 1993, Pages 421-427

https://doi.org/10.1016/0006-2952(93)90079-C Get rights and content

Abstract

Halichondrin B is a polyether macrolide of marine origin which binds to tubulin and inhibits microtubule assembly in vitro and in vivo. As is the case with phomopsin A and dolastatin 10, halichondrin B is a non-competitive inhibitor of vinblastine binding to tubulin. Analogous to maytansine, which by contrast is a competitive inhibitor of vinblastine binding, halichondrin B has no effect on colchicine binding, which is greatly stabilized by phomopsin A and dolastatin 10, but not by maytansine. We have previously developed assays which allow sensitive discrimination among the interactions of various ligands with tubulin, and examined the effects of ligands on the reactivity of tubulin sulfhydryl groups and the exposure of hydrophobic areas on the surface of the tubulin molecule. To classify the nature of the interaction between halichondrin B and tubulin, in this study we examined the effects of halichondrin B and its closely related analogue, homohalichondrin B, by these assays. We found that: (1) halichondrin B and homohalichondrin B both inhibited formation of an intra-chain cross-link between two sulfhydryl groups in β-tubulin, as do phomopsin A, dolastatin 10, maytansine, and vinblastine; (2) halichondrin B resembles maytansine in that it had no effect on alkylation of tubulin sulfhydryl groups by iodoacetamide, unlike phomopsin A, dolastatin 10 and vinblastine, all of which inhibit alkylation; (3) halichondrin B differs from other anti-mitotic drugs in that it enhanced exposure of hydrophobic areas on tubulin; (4) homohalichondrin B, like maytansine and in contrast to phomopsin A, dolastatin 10 and vinblastine, had no effect on exposure of hydrophobic areas; and (5) homohalichondrin B, contrary to maytansine, inhibited alkylation of tubulin sulfhydryl groups in the presence of GTP and MgCl₂. In their interactions with the tubulin molecule, halichondrin B and homohalichondrin B appear to have unique conformational effects which differ from those of other drugs and also from the effects of each other as well.

References (33)

RF Luduena et al.
Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents
Pharmacol Ther
(1991)
MC Roach et al.
Different effects of tubulin ligands on the intrachain cross-linking of β₁₋ tubulin
J Biol Chem
(1984)
M Little et al.
Location of two cysteines in brain β₁-tubulin that can be cross-linked after removal of exchangeable GTP
Biochim Biophys Acta
(1987)
RF Luduena et al.
Contrasting effects of maytansine and vinblastine on the alkylation of tubulin sulfhydryls
Arch Biochem Biophys
(1981)
MC Roach et al.
The effects of colchicine analogues on the reaction of tubulin with iodo[¹⁴C]acetamide and N,N'-ethylenebis(iodoace-tamide)
J Biol Chem
(1985)
MC Roach et al.
The effect of TN-16 on the alkylation of tubulin
Biochem Biophys Res Commun
(1985)
P Horowitz et al.
Bis(1,8-anilinonaphthalenesulfonate). A novel and potent inhibitor of microtubule assembly
J Biol Chem
(1984)
RF Luduena et al.
The effects of the anilinonaphthalenesulfonates on the alkylation of tubulin: Correlation between the appearance of sulfhydryl groups and apolar binding sites
Biochim Biophys Acta
(1986)
R Bai et al.
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic alkaloid sites
J Biol Chem
(1990)
RF Luduen̄a et al.
The interaction of phomopsin A with bovine brain tubulin
Arch Biochem Biophys
(1989)

RF Luduen̄a et al.

Effect of phomopsin A on the alkylation of tubulin

Biochem Pharmacol

(1990)

RF Luduen̄a et al.

Interaction of dolastatin 10 with bovine brain tubulin

Biochem Pharmacol

(1992)

B Bhattacharyya et al.

Maytansine binding to the vinblastine sites of tubulin

FEBS Lett

(1977)

F Mandelbaum-Shavit et al.

Binding of maytansine to rat brain tubulin

Biochem Biophys Res Commun

(1976)

M Takahashi et al.

Rhizoxin binding to tubulin at the maytansine-binding site

Biochim Biophys Acta

(1987)

R Bai et al.

Halichondrin B and homohalichondrin B, marine natural products binding in the Vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

J. Biol Chem

(1991)

Cited by (74)

Gram-Scale Synthesis of the C14-C23 Fragment of Eribulin
2023, Organic Process Research and Development
Eribulin is a structurally simplified and completely synthetic analogue of macrocyclic ketone halichondrin B. In 2010, eribulin was approved by FDA for the treatment of metastatic breast cancer (MBC). Although several research groups have reported the synthetic efforts toward eribulin, it is still a challenge to prepare eribulin in a large scale due to its complex molecular architecture. Herein, we report a novel and efficient route to the C14–C23 fragment of eribulin from cheap l-arabinose.
Applications of Claisen condensations in total synthesis of natural products. An old reaction, a new perspective
2022, Tetrahedron
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
2018, Cancer Treatment Reviews
Eribulin mesylate (eribulin) is a synthetic analogue of the marine-sponge natural product halichondrin B. Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell types in vitro and in vivo, and is used for the treatment of certain patients with advanced breast cancer or liposarcoma who are refractory to other treatments. The antiproliferative effects of eribulin have long been attributed to its antimitotic activities. Unlike other microtubule-targeting agents, eribulin inhibits microtubule polymerization through specific plus end binding, thus interfering with microtubule dynamic instability. Non-mitotic effects of eribulin on tumor biology have also been established in laboratory settings including: tumor vasculature remodeling, increased vascular perfusion, reduced hypoxia, and phenotypic changes involving reversal of epithelial-to-mesenchymal transition (EMT), resulting in reduced capacities for migration, invasion, and seeding lung metastases in experimental models. Preclinical data suggest that increased perfusion following eribulin treatment improves delivery of subsequent drugs. Supporting evidence for eribulin’s non-mitotic effects in the clinical setting include increased tumor oxygen saturation, reduced hypoxia, phenotype changes consistent with EMT reversal, and genotype changes consistent with shifts from nonendocrine-responsive, luminal B, to endocrine-responsive, luminal A, breast cancer subtypes. Finally, potential biomarkers for eribulin response have been established based on tumor-phenotype and gene-expression profiles. Overall, preclinical and clinical data support both antimitotic and non-mitotic mechanisms of eribulin that may underlie the survival benefit observed in various clinical trials.
Synthesis of the C38-C54 spiroketal segment of halichondrin B
2012, Tetrahedron Letters
Epothilones in development for non-small-cell lung cancer: Novel anti-tubulin agents with the potential to overcome taxane resistance
2012, Clinical Lung Cancer
Citation Excerpt :
The epothilones appear to overcome one of the major mechanisms of resistance to taxanes and other anti-tubulin agents, β III tubulin overexpression.7,8 There is differential, tissue-specific expression of tubulin isotypes (Table 1).7,9-13 Class III β-tubulin (cIII β-t) is a minor neuronal polypeptide which is normally expressed at low levels only in neurons and Sertoli cells.
Progress in the treatment of non–small-cell lung cancer (NSCLC) will require the introduction of new agents as well as better use of existing therapies. Targeted therapies are likely to have a profound effect on the treatment of NSCLC after identification of patients who are most likely to benefit. The epothilones are novel anti-tubulin agents derived from Sorangium cellulosum. β III tubulin overexpression has been implicated as a mechanism of anti-tubulin resistance that can be overcome by epothilones. Several epothilones have advanced to clinical trials; ixabepilone (BMS247550, aza-epothilone B, Bristol-Myers Squibb, New York, NY), patupilone (EPO906, Novartis, Basel, Switzerland) and sagopilone (ZK-EPO, ZK-219477, Schering AG, Berlin-Wedding, Germany) are currently in active development. Several of the epothilones, most notably ixabepilone, have demonstrated activity in lung cancer in phase I and II trials, including taxane-resistant patients. Although a phase II study failed to show superior outcome in patients with β III tubulin overexpression, other aspects of the epothilones argue for their continued development.
Eribulin-A review of preclinical and clinical studies
2012, Critical Reviews in Oncology/Hematology
Citation Excerpt :
Also the pathological changes in mice at equivalent half MTD or higher doses in dorsal and sciatic root ganglia were milder and less frequent with eribulin as compared to ixabepilone and paclitaxel[30]. Halichondrin B binds tubulin at a site close to the vinca site altering depolymerization [7], with no effect on colchicine binding [9]. It inhibits the formation of an intra-chain cross-link between two sulfhydryl groups in β-tubulin, does not affects alkylation of tubulin sulfhydryl groups by iodoacetamide (unlike vinblastine) and enhances the exposure of hydrophobic areas on the tubulin molecule.
Eribulin mesylate is a non-taxane, structurally simplified, completely synthetic, halichondrin B derivative with an end poisoning, microtubule inhibitory action. Preclinical studies have demonstrated activity in various cancer cell lines and synergistic action with gemcitabine, epirubicin, trastuzumab, cisplatin, docetaxel and vinorelbine. Eribulin has recently been approved by United States Food and Drug Administration as a third line therapy for metastatic breast cancer patients, who have previously been treated with an anthracycline and a taxane. It has also advanced to phase II trials in non-small cell lung cancer, pancreatic, prostate, bladder, head and neck cancers, sarcomas and ovarian and other gynecological tumors. Combination trials with carboplatin, gemcitabine, pemetrexed, cisplatin, and erlotinib are currently ongoing. Eribulin potentially has a low incidence of peripheral neuropathy. The predominant side effects are neutropenia and fatigue, which are manageable. This article reviews the available information on eribulin with respect to its clinical pharmacology, mechanism of action, pharmacokinetics, pharmacodynamics, metabolism, preclinical studies and clinical trials.

View all citing articles on Scopus

View full text

Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin

Abstract

Pharmacol Ther

J Biol Chem

Biochim Biophys Acta

Arch Biochem Biophys

J Biol Chem

Biochem Biophys Res Commun

J Biol Chem

Biochim Biophys Acta

J Biol Chem

Arch Biochem Biophys

Biochem Pharmacol

Biochem Pharmacol

FEBS Lett

Biochem Biophys Res Commun

Biochim Biophys Acta

J. Biol Chem